SlideShare uma empresa Scribd logo
1 de 23
Baixar para ler offline
World Tuberculosis Day 2013
TB situation in 2011:
Findings from the ECDC and WHO/EURO
joint TB surveillance report
ECDC TB Team
European Centre for Disease Prevention and Control
Stockholm, 24 March 2013
TB notification rates in EU/EEA, 2011
  In the EU/EEA, 72 334 TB cases were reported in 2011.
  Notification rate 14.2 per 100 000 population (range 2.8–89.7).
  Figure 1: Country-specific TB notification rates, 2011




< 10 per 100 000

10 to 19 per 100 000

20 to 49 per 100 000

50 to 99 per 100 000

Not included or not
reporting


                                                                    2
TB notification rates in EU/EEA, 2007−2011
Overall in the EU/EEA, notification rates have steadily declined.
Figure 2: Trend in TB notification rate in the EU/EEA 2007−2011




                                           20
Notification rate per 100 000 population




                                                  16,8   16,5
                                           15                        15,8
                                                                                    14,9
                                                                                            14,2


                                           10




                                           5
                                                2007     2008        2009           2010   2011

                                                                Year of reporting


                                                                                                   3
Proportion of confirmed* TB cases in the EU/
   EEA, 2011
   Overall 61.3% (range 27.9 – 94.8%) of TB cases reported in
   the EU/EEA were laboratory-confirmed.

   Figure 3: Country-specific
   proportion of all confirmed TB
   cases in 2011




< 60%

60 to 69%

70 to 79%

≥ 80%
Not included or
not reporting

   * Confirmed by culture or both a positive sputum microscopy result and Mycobacterium tuberculosis nucleic acid identified in nucleic
   acid amplification test.                                                                                                               4
TB notification rates in children <15 years
  of age in EU/EEA, 2011
  In 2011, 3 190 cases of TB in children were reported,
  accounting for 4.4% of all notified TB cases
  (range 0 – 11.1%) in the EU/EEA.
  Figure 4: Country-specific childhood TB
  notification rates among child population
  (0–14 years), 2011



 < 2 per
100 000 child population

2 to 3.9 per
100 000 child population

4 to 9.9 per
100 000 child population

≥ 10 per
100 000 child population

Not included or not
reporting


                                                          5
Proportion of foreign origin among notified
   TB cases in EU/EEA, 2011
   In 2011, the overall proportion of TB cases of foreign origin in
   the EU/EEA was 25.8% (range 0.3 – 89.4%).

   Figure 5: Country-specific
   proportion of foreign origin cases
   among all notified
   TB cases, EU/EEA, 2011



< 1%

1 to 24%

25 to 49%

50 to 74%

≥ 75%

Not included or
not reporting


                                                                      6
Proportion of notified extrapulmonary
   TB cases in EU/EEA, 2011
   In 2011, the overall proportion of extrapulmonary TB cases in
   the EU/EEA was 22.3% (range 3.9 – 66.7%).

   Figure 6: Country-specific proportion
   of extrapulmonary TB of all notified
   TB cases, EU/EEA, 2011




< 1%

1 to 19%

20 to 29%

30 to 49%

≥ 50%

Not included or
not reporting


                                                                   7
Extrapulmonary TB notification rates in
                         EU/EEA, 2002−2011
                         Extrapulmonary TB notification rates have remained stable in the last 10 years.
                         Figure 7: Trend in extrapulmonary TB notification rate
                         in the EU/EEA, 2002−2011


                                           5
Notification rate per 100 000 population




                                           4


                                           3    3,4   3,4    3,5           3,4                 3,5    3,4
                                                                    3,3                3,2                   3,3
                                                                                                                    3,2

                                           2


                                           1


                                           0
                                               2002   2003   2004   2005   2006       2007     2008   2009   2010   2011
                                                                           Year of reporting


                                                                                                                           8
Proportions of TB by site among all notified
TB cases in EU/EEA, 2002−2011
Percentage of extrapulmonary TB increased from 16.4% in 2002 to 22.4% in 2011.
Figure 8: Proportion of notified pulmonary and
extrapulmonary TB cases in the EU/EEA, 2002−2011



Number of cases
100000                                                        Pulmonary TB   Extrapulmonary TB
 90000
 80000
 70000
 60000
 50000
 40000
 30000
 20000
 10000
      0
             2002   2003   2004   2005       2006     2007   2008     2009     2010      2011

                                         Year of reporting


                                                                                                 9
Proportion of culture-confirmed new
      pulmonary TB cases in EU/EEA, 2011
      61% of new pulmonary TB cases were culture-confirmed.
      The proportion varied widely across countries (range 33 – 98%).

      Figure 9: Proportion of new pulmonary TB cases confirmed by culture, 2011


             100
             90
             80
             70
Percentage




             60
             50
             40
             30
             20
             10
              0




                                                                                  10
Proportion of notified TB cases with multi-
   drug resistance among all confirmed TB
   cases in EU/EEA, 2011
   In 2011, the overall proportion of TB cases with multi-drug
   resistance in the EU/EEA was 4.5% (range 0 – 29.8%).
   Figure 10: Country-specific proportion
   of multidrug resistance among all
   confirmed TB cases,
   EU/EEA, 2011


< 1%

1 to 1.9%

2 to 4.9%

5 to 9.9%

≥ 10%

Not included or
not reporting


                                                                 11
Proportion of notified new TB cases with
   multidrug resistance in EU/EEA, 2011
   In 2011, the overall proportion of new TB cases with multi-
   drug resistance in the EU/EEA was 2.4% (range 0 – 23.3%).

   Figure 11: Country-specific
   proportion of new TB cases with
   multidrug resistance,
   EU/EEA, 2011



< 1%

1 to 1.9%

2 to 4.9%

5 to 9.9%

≥ 10%

Not included or
not reporting


                                                                 12
Notification rates of new cases with
multidrug resistant TB in EU/EEA, 2007−2011

The notification rate of multidrug resistant TB have remained stable at around
0.3 per 100 000 population.

Figure 12: Trends in multidrug resistant TB notification rate in the EU/EEA,
2007−2011

                                            0,4
 Notification rate per 100 000 population




                                            0,3     0,33     0,35
                                                                            0,33
                                                                                         0,30     0,30

                                            0,2


                                            0,1


                                            0,0
                                                  2007     2008           2009          2010    2011
                                                                    Year of reporting


                                                                                                         13
Proportion of notified previously treated
   TB cases with multidrug resistance in EU/
   EEA, 2011
   In 2011, the overall proportion of previously treated TB cases
   with multidrug resistance in the EU/EEA was 16.8%
   (range 0 – 57.7%).
   Figure 13: Country-specific
   proportion of previously
   treated TB cases with
   multi-drug resistance,
   EU/EEA, 2011
< 1%

1 to 1.9%

2 to 4.9%

5 to 9.9%

≥ 10%

Not included or
not reporting


                                                                    14
Proportion of TB cases with extensive drug
   resistance among MDR-TB cases with SLD
   ST* reported in EU/EEA, 2011
   In 2011, the proportion of extensive drug resistant cases among
   cases with multidrug resistance in EU/EEA was 13.4%
   (range 0 – 40.0%).
   Figure 14: Country-specific proportion of extensively
   drug-resistant TB cases
   among TB cases with
   multi-drug resistance,
   EU/EEA, 2011
< 1%

1 to 4%

5 to 9%

10 to 19%

≥ 20% or
Not included or
Not included
not reporting
not reporting

   *SLD ST – second line drug susceptibility testing result          15
Proportion of HIV positive TB cases among
   all TB cases with known HIV status in EU/
   EEA, 2011
   In 2011, the overall proportion of HIV positive TB cases
   among TB cases with known HIV status in EU/EEA was 4.7%
   (range 0 – 40%).
   Figure 15: Country-specific proportion of
   HIV positive TB cases
   among TB cases with
   known HIV status,
   EU/EEA, 2011
< 1%

1 to 1.9%

2 to 4.9%

5 to 9.9%

≥ 10%

Not included or
not reporting


                                                              16
Treatment success rate for new pulmonary
TB cases in EU/EEA*, 2010
The treatment success rate for new culture-confirmed pulmonary TB cases notified in
2010 was 76.8% (range: 0 – 91.4%).
Figure 16: Treatment success rate for new culture-confirmed
pulmonary TB cases notified in 2010


                        100
Treatment success (%)




                        80


                        60


                        40


                        20


                         0




* Five EU/EEA Member States did not report treatment outcome data.
                                                                                      17
Treatment success rate for new
pulmonary TB cases by year of reporting
in EU/EEA, 2006−2010
The treatment success rate for new culture-confirmed pulmonary TB cases notified
between 2006 and 2010 has slightly decreased from 79.5% in 2006 to 76.8% in 2010.
Figure 17: Treatment success rate for new culture-confirmed pulmonary
TB cases notified in 2006−2010
                        100


                        80
Treatment success (%)




                                 79,5   79,2      79,5             78,9     76,8
                        60


                        40


                        20


                         0
                              2006      2007     2008              2009    2010
                                               Year of reporting

                                                                                    18
Treatment success rate for previously
  treated pulmonary TB cases in EU/EEA*,
  2010
  The treatment success rate for previously treated culture-confirmed pulmonary
  TB cases notified in 2010 was 53.7% (range 31.4 – 85.7%).
  Figure 18: Treatment success rate for previously treated culture-confirmed pulmonary
  TB cases notified in 2010
                        100
Treatment success (%)




                        80


                        60


                        40


                        20


                         0




  * Iceland and Luxembourg reported zero previously treated TB cases in 2010. Seven EU/EEA Member States did not
  report stratified treatment outcome data                                                                         19
Treatment success rate for all notified
pulmonary TB cases in EU/EEA*, 2010
The treatment success rate for all confirmed pulmonary TB cases notified
in 2010 was 74.3% (range 0 – 90.1%).
Figure 19: Treatment success rate for all confirmed pulmonary TB cases notified in
2010


                        100


                        80
Treatment success (%)




                        60


                        40


                        20


                         0




  * Five EU/EEA Member States did not report treatment outcome data
                                                                                     20
Treatment success* rate for extra-
pulmonary TB cases in EU/EEA**, 2010
The treatment success rate for extrapulmonary TB cases notified in 2010 was
82.2% (range 21.1 – 100%).
Figure 20: Treatment success rate for extrapulmonary TB cases notified in 2010



                        100


                        80
Treatment success (%)




                        60


                        40


                        20


                         0




* Treatment success of extrapulmonary TB consists of cases reported as completed full course of anti-tuberculosis treatment
** Seven Member States did not report stratified treatment outcome data                                                       21
Treatment success rate for notified
multidrug-resistant TB cases in EU/EEA*,
2009
The treatment success rate for all confirmed multidrug-resistant TB cases notified in
2009 was 31.6% (range 0 – 84.6%).
Figure 21: Treatment success rate for all confirmed multidrug-resistant TB
cases notified in 2009
                        100


                        80
Treatment success (%)




                        60


                        40


                        20


                         0




* Malta reported zero MDR TB cases in 2009, 11 Member States did not report treatment outcome data
                                                                                                     22
Treatment outcome for multidrug-resistant
TB cases notified in 2007−2009
Treatment outcomes for multidrug-resistant TB cases did not improve between the
2007 and 2009 cohort, EU/EEA.
Figure 22: Treatment outcome at 24 months for multidrug-resistant TB cases
diagnosed in 2009, compared with cases diagnosed in 2007 and 2008

             35
                                                              cohort 2009 (18 countries)
             30

                                                              cohort 2008 (20 countries)
             25

                                                              cohort 2007 (15 countries)
Percentage




             20

             15

             10

             5

             0
                  Success   Died     Failed      Defaulted     Still on     Transferred or
                                                             treatment         unknown

                                                                                             23

Mais conteúdo relacionado

Semelhante a TB situation in 2011:Findings from the ECDC and WHO/EURO joint TB surveillance report

Simon stevens presentation - future nhs stage, 12.00, 2 september 2015
Simon stevens presentation - future nhs stage, 12.00, 2 september 2015Simon stevens presentation - future nhs stage, 12.00, 2 september 2015
Simon stevens presentation - future nhs stage, 12.00, 2 september 2015NHS England
 
PPT Besozzi "TB: a system disease"
PPT Besozzi "TB: a system disease"PPT Besozzi "TB: a system disease"
PPT Besozzi "TB: a system disease"StopTb Italia
 
Sickle Cell Disease: Newborn screening in France and the UK - Jacques Elion
Sickle Cell Disease: Newborn screening in France and the UK - Jacques ElionSickle Cell Disease: Newborn screening in France and the UK - Jacques Elion
Sickle Cell Disease: Newborn screening in France and the UK - Jacques ElionHuman Variome Project
 
Basic concepts of tuberculosis
Basic concepts of tuberculosisBasic concepts of tuberculosis
Basic concepts of tuberculosisAshraf ElAdawy
 
Questionig the usefluness of the tuberculosis infection (LTBI) surveillance i...
Questionig the usefluness of the tuberculosis infection (LTBI) surveillance i...Questionig the usefluness of the tuberculosis infection (LTBI) surveillance i...
Questionig the usefluness of the tuberculosis infection (LTBI) surveillance i...Theocharopoulos Georgios Yorgos
 
B URDEN OF HOSPITALIZATIONS RELATED TO CHRONIC HEPATITIS C IN F RANCE Evoluti...
B URDEN OF HOSPITALIZATIONS RELATED TO CHRONIC HEPATITIS C IN F RANCE Evoluti...B URDEN OF HOSPITALIZATIONS RELATED TO CHRONIC HEPATITIS C IN F RANCE Evoluti...
B URDEN OF HOSPITALIZATIONS RELATED TO CHRONIC HEPATITIS C IN F RANCE Evoluti...Michel Rotily
 
Using #teledermatology effectively in rural #primarycare settings
Using #teledermatology effectively in rural #primarycare settingsUsing #teledermatology effectively in rural #primarycare settings
Using #teledermatology effectively in rural #primarycare settingsJosep Vidal-Alaball
 

Semelhante a TB situation in 2011:Findings from the ECDC and WHO/EURO joint TB surveillance report (20)

Tuberculosis situation in the EU/EEA, 2018
Tuberculosis situation in the EU/EEA, 2018Tuberculosis situation in the EU/EEA, 2018
Tuberculosis situation in the EU/EEA, 2018
 
TB DAY 2022 - Ritorno al futuro
TB DAY 2022 - Ritorno al futuroTB DAY 2022 - Ritorno al futuro
TB DAY 2022 - Ritorno al futuro
 
Simon stevens presentation - future nhs stage, 12.00, 2 september 2015
Simon stevens presentation - future nhs stage, 12.00, 2 september 2015Simon stevens presentation - future nhs stage, 12.00, 2 september 2015
Simon stevens presentation - future nhs stage, 12.00, 2 september 2015
 
PPT Besozzi "TB: a system disease"
PPT Besozzi "TB: a system disease"PPT Besozzi "TB: a system disease"
PPT Besozzi "TB: a system disease"
 
Sickle Cell Disease: Newborn screening in France and the UK - Jacques Elion
Sickle Cell Disease: Newborn screening in France and the UK - Jacques ElionSickle Cell Disease: Newborn screening in France and the UK - Jacques Elion
Sickle Cell Disease: Newborn screening in France and the UK - Jacques Elion
 
Efsa zoonoses 2009
Efsa zoonoses 2009Efsa zoonoses 2009
Efsa zoonoses 2009
 
Tuberculosis and HIV co-infection in the European Union: Epidemiology and tre...
Tuberculosis and HIV co-infection in the European Union: Epidemiology and tre...Tuberculosis and HIV co-infection in the European Union: Epidemiology and tre...
Tuberculosis and HIV co-infection in the European Union: Epidemiology and tre...
 
Human campylobacteriosis in the European Union
Human campylobacteriosis in the European UnionHuman campylobacteriosis in the European Union
Human campylobacteriosis in the European Union
 
Basic concepts of tuberculosis
Basic concepts of tuberculosisBasic concepts of tuberculosis
Basic concepts of tuberculosis
 
World TB Day 2017 - presentation
World TB Day 2017 - presentationWorld TB Day 2017 - presentation
World TB Day 2017 - presentation
 
Questionig the usefluness of the tuberculosis infection (LTBI) surveillance i...
Questionig the usefluness of the tuberculosis infection (LTBI) surveillance i...Questionig the usefluness of the tuberculosis infection (LTBI) surveillance i...
Questionig the usefluness of the tuberculosis infection (LTBI) surveillance i...
 
Tuberculosis situation in the EU/EEA, 2019
Tuberculosis situation in the EU/EEA, 2019Tuberculosis situation in the EU/EEA, 2019
Tuberculosis situation in the EU/EEA, 2019
 
Association between influenza virus subtypes in consecutive influenza seasons...
Association between influenza virus subtypes in consecutive influenza seasons...Association between influenza virus subtypes in consecutive influenza seasons...
Association between influenza virus subtypes in consecutive influenza seasons...
 
The diverse and dynamic epidemics of hepatitis B and C in the EU: challenges ...
The diverse and dynamic epidemics of hepatitis B and C in the EU: challenges ...The diverse and dynamic epidemics of hepatitis B and C in the EU: challenges ...
The diverse and dynamic epidemics of hepatitis B and C in the EU: challenges ...
 
B URDEN OF HOSPITALIZATIONS RELATED TO CHRONIC HEPATITIS C IN F RANCE Evoluti...
B URDEN OF HOSPITALIZATIONS RELATED TO CHRONIC HEPATITIS C IN F RANCE Evoluti...B URDEN OF HOSPITALIZATIONS RELATED TO CHRONIC HEPATITIS C IN F RANCE Evoluti...
B URDEN OF HOSPITALIZATIONS RELATED TO CHRONIC HEPATITIS C IN F RANCE Evoluti...
 
HIV infection in children and adolescents in the EU/EEA 2015
HIV infection in children and adolescents in the EU/EEA 2015HIV infection in children and adolescents in the EU/EEA 2015
HIV infection in children and adolescents in the EU/EEA 2015
 
Variable Syrup used for consumption in children. Mike Sharland (UK)
Variable Syrup used for consumption in children. Mike Sharland (UK)Variable Syrup used for consumption in children. Mike Sharland (UK)
Variable Syrup used for consumption in children. Mike Sharland (UK)
 
12889 2017 article_4544
12889 2017 article_454412889 2017 article_4544
12889 2017 article_4544
 
Monitoring viral hepatitis elimination across EU/EEA countries
Monitoring viral hepatitis elimination across EU/EEA countriesMonitoring viral hepatitis elimination across EU/EEA countries
Monitoring viral hepatitis elimination across EU/EEA countries
 
Using #teledermatology effectively in rural #primarycare settings
Using #teledermatology effectively in rural #primarycare settingsUsing #teledermatology effectively in rural #primarycare settings
Using #teledermatology effectively in rural #primarycare settings
 

Mais de StopTb Italia

PPT Messa "Un tributo pagato dall'arte"
PPT Messa "Un tributo pagato dall'arte"PPT Messa "Un tributo pagato dall'arte"
PPT Messa "Un tributo pagato dall'arte"StopTb Italia
 
PPT Rizzardini "HAART, sostenibilità di un miracolo"
PPT Rizzardini "HAART, sostenibilità di un miracolo"PPT Rizzardini "HAART, sostenibilità di un miracolo"
PPT Rizzardini "HAART, sostenibilità di un miracolo"StopTb Italia
 
PPT Ranieri "HIV e TB in carcere"
PPT Ranieri "HIV e TB in carcere"PPT Ranieri "HIV e TB in carcere"
PPT Ranieri "HIV e TB in carcere"StopTb Italia
 
PPT Fiorentini "TB tra ospedale e territorio"
PPT Fiorentini "TB tra ospedale e territorio"PPT Fiorentini "TB tra ospedale e territorio"
PPT Fiorentini "TB tra ospedale e territorio"StopTb Italia
 
PPT Rusconi "Le multiresistenze dell'HIV/AIDS"
PPT Rusconi "Le multiresistenze dell'HIV/AIDS"PPT Rusconi "Le multiresistenze dell'HIV/AIDS"
PPT Rusconi "Le multiresistenze dell'HIV/AIDS"StopTb Italia
 
PPT Besozzi "Le multiresistenze della TB"
PPT Besozzi "Le multiresistenze della TB"PPT Besozzi "Le multiresistenze della TB"
PPT Besozzi "Le multiresistenze della TB"StopTb Italia
 
PPT Motta "La farmacologia clinica nella infezione e coinfezione TB/HIV"
PPT Motta "La farmacologia clinica nella infezione e coinfezione TB/HIV"PPT Motta "La farmacologia clinica nella infezione e coinfezione TB/HIV"
PPT Motta "La farmacologia clinica nella infezione e coinfezione TB/HIV"StopTb Italia
 
PPT Concia "Localizzazioni extrapolmonari nella coinfezione"
PPT Concia "Localizzazioni extrapolmonari nella coinfezione"PPT Concia "Localizzazioni extrapolmonari nella coinfezione"
PPT Concia "Localizzazioni extrapolmonari nella coinfezione"StopTb Italia
 
PPT Lapadula "Clinica e terapia in TB/HIV"
PPT Lapadula "Clinica e terapia in TB/HIV"PPT Lapadula "Clinica e terapia in TB/HIV"
PPT Lapadula "Clinica e terapia in TB/HIV"StopTb Italia
 
PPT Bonora "Clinica e terapia dell'HIV"
PPT Bonora "Clinica e terapia dell'HIV"PPT Bonora "Clinica e terapia dell'HIV"
PPT Bonora "Clinica e terapia dell'HIV"StopTb Italia
 
PPT Cirillo "La diagnosi di tubercolosi"
PPT Cirillo "La diagnosi di tubercolosi"PPT Cirillo "La diagnosi di tubercolosi"
PPT Cirillo "La diagnosi di tubercolosi"StopTb Italia
 
PPT Gori "Immunologia TB/HIV"
PPT Gori "Immunologia TB/HIV"PPT Gori "Immunologia TB/HIV"
PPT Gori "Immunologia TB/HIV"StopTb Italia
 
PPT Castelli "Dall'HIV all'AIDS fino alla coinfezione: una diagnosi difficile?"
PPT Castelli "Dall'HIV all'AIDS fino alla coinfezione: una diagnosi difficile?"PPT Castelli "Dall'HIV all'AIDS fino alla coinfezione: una diagnosi difficile?"
PPT Castelli "Dall'HIV all'AIDS fino alla coinfezione: una diagnosi difficile?"StopTb Italia
 
PPT Bocchino "Diagnosi dell'infezione tubercolare"
PPT Bocchino "Diagnosi dell'infezione tubercolare"PPT Bocchino "Diagnosi dell'infezione tubercolare"
PPT Bocchino "Diagnosi dell'infezione tubercolare"StopTb Italia
 
PPT Angarano "Storia naturale dell'HIV"
PPT Angarano "Storia naturale dell'HIV"PPT Angarano "Storia naturale dell'HIV"
PPT Angarano "Storia naturale dell'HIV"StopTb Italia
 
PPT Casali "Storia naturale della TB"
PPT Casali "Storia naturale della TB"PPT Casali "Storia naturale della TB"
PPT Casali "Storia naturale della TB"StopTb Italia
 
PPT Girardi "Epidemiologia della confezione TB-HIV"
PPT Girardi "Epidemiologia della confezione TB-HIV"PPT Girardi "Epidemiologia della confezione TB-HIV"
PPT Girardi "Epidemiologia della confezione TB-HIV"StopTb Italia
 
PPT Pezzotti "Epidemiologia dell'HIV"
PPT Pezzotti "Epidemiologia dell'HIV"PPT Pezzotti "Epidemiologia dell'HIV"
PPT Pezzotti "Epidemiologia dell'HIV"StopTb Italia
 
PPT Matteelli "Epidemiologia della TB"
PPT Matteelli "Epidemiologia della TB"PPT Matteelli "Epidemiologia della TB"
PPT Matteelli "Epidemiologia della TB"StopTb Italia
 

Mais de StopTb Italia (20)

PPT Messa "Un tributo pagato dall'arte"
PPT Messa "Un tributo pagato dall'arte"PPT Messa "Un tributo pagato dall'arte"
PPT Messa "Un tributo pagato dall'arte"
 
PPT Rizzardini "HAART, sostenibilità di un miracolo"
PPT Rizzardini "HAART, sostenibilità di un miracolo"PPT Rizzardini "HAART, sostenibilità di un miracolo"
PPT Rizzardini "HAART, sostenibilità di un miracolo"
 
PPT Ranieri "HIV e TB in carcere"
PPT Ranieri "HIV e TB in carcere"PPT Ranieri "HIV e TB in carcere"
PPT Ranieri "HIV e TB in carcere"
 
PPT Fiorentini "TB tra ospedale e territorio"
PPT Fiorentini "TB tra ospedale e territorio"PPT Fiorentini "TB tra ospedale e territorio"
PPT Fiorentini "TB tra ospedale e territorio"
 
PPT Rusconi "Le multiresistenze dell'HIV/AIDS"
PPT Rusconi "Le multiresistenze dell'HIV/AIDS"PPT Rusconi "Le multiresistenze dell'HIV/AIDS"
PPT Rusconi "Le multiresistenze dell'HIV/AIDS"
 
PPT Besozzi "Le multiresistenze della TB"
PPT Besozzi "Le multiresistenze della TB"PPT Besozzi "Le multiresistenze della TB"
PPT Besozzi "Le multiresistenze della TB"
 
PPT Motta "La farmacologia clinica nella infezione e coinfezione TB/HIV"
PPT Motta "La farmacologia clinica nella infezione e coinfezione TB/HIV"PPT Motta "La farmacologia clinica nella infezione e coinfezione TB/HIV"
PPT Motta "La farmacologia clinica nella infezione e coinfezione TB/HIV"
 
PPT Concia "Localizzazioni extrapolmonari nella coinfezione"
PPT Concia "Localizzazioni extrapolmonari nella coinfezione"PPT Concia "Localizzazioni extrapolmonari nella coinfezione"
PPT Concia "Localizzazioni extrapolmonari nella coinfezione"
 
PPT Lapadula "Clinica e terapia in TB/HIV"
PPT Lapadula "Clinica e terapia in TB/HIV"PPT Lapadula "Clinica e terapia in TB/HIV"
PPT Lapadula "Clinica e terapia in TB/HIV"
 
PPT Bonora "Clinica e terapia dell'HIV"
PPT Bonora "Clinica e terapia dell'HIV"PPT Bonora "Clinica e terapia dell'HIV"
PPT Bonora "Clinica e terapia dell'HIV"
 
PPT Casali
PPT CasaliPPT Casali
PPT Casali
 
PPT Cirillo "La diagnosi di tubercolosi"
PPT Cirillo "La diagnosi di tubercolosi"PPT Cirillo "La diagnosi di tubercolosi"
PPT Cirillo "La diagnosi di tubercolosi"
 
PPT Gori "Immunologia TB/HIV"
PPT Gori "Immunologia TB/HIV"PPT Gori "Immunologia TB/HIV"
PPT Gori "Immunologia TB/HIV"
 
PPT Castelli "Dall'HIV all'AIDS fino alla coinfezione: una diagnosi difficile?"
PPT Castelli "Dall'HIV all'AIDS fino alla coinfezione: una diagnosi difficile?"PPT Castelli "Dall'HIV all'AIDS fino alla coinfezione: una diagnosi difficile?"
PPT Castelli "Dall'HIV all'AIDS fino alla coinfezione: una diagnosi difficile?"
 
PPT Bocchino "Diagnosi dell'infezione tubercolare"
PPT Bocchino "Diagnosi dell'infezione tubercolare"PPT Bocchino "Diagnosi dell'infezione tubercolare"
PPT Bocchino "Diagnosi dell'infezione tubercolare"
 
PPT Angarano "Storia naturale dell'HIV"
PPT Angarano "Storia naturale dell'HIV"PPT Angarano "Storia naturale dell'HIV"
PPT Angarano "Storia naturale dell'HIV"
 
PPT Casali "Storia naturale della TB"
PPT Casali "Storia naturale della TB"PPT Casali "Storia naturale della TB"
PPT Casali "Storia naturale della TB"
 
PPT Girardi "Epidemiologia della confezione TB-HIV"
PPT Girardi "Epidemiologia della confezione TB-HIV"PPT Girardi "Epidemiologia della confezione TB-HIV"
PPT Girardi "Epidemiologia della confezione TB-HIV"
 
PPT Pezzotti "Epidemiologia dell'HIV"
PPT Pezzotti "Epidemiologia dell'HIV"PPT Pezzotti "Epidemiologia dell'HIV"
PPT Pezzotti "Epidemiologia dell'HIV"
 
PPT Matteelli "Epidemiologia della TB"
PPT Matteelli "Epidemiologia della TB"PPT Matteelli "Epidemiologia della TB"
PPT Matteelli "Epidemiologia della TB"
 

TB situation in 2011:Findings from the ECDC and WHO/EURO joint TB surveillance report

  • 1. World Tuberculosis Day 2013 TB situation in 2011: Findings from the ECDC and WHO/EURO joint TB surveillance report ECDC TB Team European Centre for Disease Prevention and Control Stockholm, 24 March 2013
  • 2. TB notification rates in EU/EEA, 2011 In the EU/EEA, 72 334 TB cases were reported in 2011. Notification rate 14.2 per 100 000 population (range 2.8–89.7). Figure 1: Country-specific TB notification rates, 2011 < 10 per 100 000 10 to 19 per 100 000 20 to 49 per 100 000 50 to 99 per 100 000 Not included or not reporting 2
  • 3. TB notification rates in EU/EEA, 2007−2011 Overall in the EU/EEA, notification rates have steadily declined. Figure 2: Trend in TB notification rate in the EU/EEA 2007−2011 20 Notification rate per 100 000 population 16,8 16,5 15 15,8 14,9 14,2 10 5 2007 2008 2009 2010 2011 Year of reporting 3
  • 4. Proportion of confirmed* TB cases in the EU/ EEA, 2011 Overall 61.3% (range 27.9 – 94.8%) of TB cases reported in the EU/EEA were laboratory-confirmed. Figure 3: Country-specific proportion of all confirmed TB cases in 2011 < 60% 60 to 69% 70 to 79% ≥ 80% Not included or not reporting * Confirmed by culture or both a positive sputum microscopy result and Mycobacterium tuberculosis nucleic acid identified in nucleic acid amplification test. 4
  • 5. TB notification rates in children <15 years of age in EU/EEA, 2011 In 2011, 3 190 cases of TB in children were reported, accounting for 4.4% of all notified TB cases (range 0 – 11.1%) in the EU/EEA. Figure 4: Country-specific childhood TB notification rates among child population (0–14 years), 2011 < 2 per 100 000 child population 2 to 3.9 per 100 000 child population 4 to 9.9 per 100 000 child population ≥ 10 per 100 000 child population Not included or not reporting 5
  • 6. Proportion of foreign origin among notified TB cases in EU/EEA, 2011 In 2011, the overall proportion of TB cases of foreign origin in the EU/EEA was 25.8% (range 0.3 – 89.4%). Figure 5: Country-specific proportion of foreign origin cases among all notified TB cases, EU/EEA, 2011 < 1% 1 to 24% 25 to 49% 50 to 74% ≥ 75% Not included or not reporting 6
  • 7. Proportion of notified extrapulmonary TB cases in EU/EEA, 2011 In 2011, the overall proportion of extrapulmonary TB cases in the EU/EEA was 22.3% (range 3.9 – 66.7%). Figure 6: Country-specific proportion of extrapulmonary TB of all notified TB cases, EU/EEA, 2011 < 1% 1 to 19% 20 to 29% 30 to 49% ≥ 50% Not included or not reporting 7
  • 8. Extrapulmonary TB notification rates in EU/EEA, 2002−2011 Extrapulmonary TB notification rates have remained stable in the last 10 years. Figure 7: Trend in extrapulmonary TB notification rate in the EU/EEA, 2002−2011 5 Notification rate per 100 000 population 4 3 3,4 3,4 3,5 3,4 3,5 3,4 3,3 3,2 3,3 3,2 2 1 0 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 Year of reporting 8
  • 9. Proportions of TB by site among all notified TB cases in EU/EEA, 2002−2011 Percentage of extrapulmonary TB increased from 16.4% in 2002 to 22.4% in 2011. Figure 8: Proportion of notified pulmonary and extrapulmonary TB cases in the EU/EEA, 2002−2011 Number of cases 100000 Pulmonary TB Extrapulmonary TB 90000 80000 70000 60000 50000 40000 30000 20000 10000 0 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 Year of reporting 9
  • 10. Proportion of culture-confirmed new pulmonary TB cases in EU/EEA, 2011 61% of new pulmonary TB cases were culture-confirmed. The proportion varied widely across countries (range 33 – 98%). Figure 9: Proportion of new pulmonary TB cases confirmed by culture, 2011 100 90 80 70 Percentage 60 50 40 30 20 10 0 10
  • 11. Proportion of notified TB cases with multi- drug resistance among all confirmed TB cases in EU/EEA, 2011 In 2011, the overall proportion of TB cases with multi-drug resistance in the EU/EEA was 4.5% (range 0 – 29.8%). Figure 10: Country-specific proportion of multidrug resistance among all confirmed TB cases, EU/EEA, 2011 < 1% 1 to 1.9% 2 to 4.9% 5 to 9.9% ≥ 10% Not included or not reporting 11
  • 12. Proportion of notified new TB cases with multidrug resistance in EU/EEA, 2011 In 2011, the overall proportion of new TB cases with multi- drug resistance in the EU/EEA was 2.4% (range 0 – 23.3%). Figure 11: Country-specific proportion of new TB cases with multidrug resistance, EU/EEA, 2011 < 1% 1 to 1.9% 2 to 4.9% 5 to 9.9% ≥ 10% Not included or not reporting 12
  • 13. Notification rates of new cases with multidrug resistant TB in EU/EEA, 2007−2011 The notification rate of multidrug resistant TB have remained stable at around 0.3 per 100 000 population. Figure 12: Trends in multidrug resistant TB notification rate in the EU/EEA, 2007−2011 0,4 Notification rate per 100 000 population 0,3 0,33 0,35 0,33 0,30 0,30 0,2 0,1 0,0 2007 2008 2009 2010 2011 Year of reporting 13
  • 14. Proportion of notified previously treated TB cases with multidrug resistance in EU/ EEA, 2011 In 2011, the overall proportion of previously treated TB cases with multidrug resistance in the EU/EEA was 16.8% (range 0 – 57.7%). Figure 13: Country-specific proportion of previously treated TB cases with multi-drug resistance, EU/EEA, 2011 < 1% 1 to 1.9% 2 to 4.9% 5 to 9.9% ≥ 10% Not included or not reporting 14
  • 15. Proportion of TB cases with extensive drug resistance among MDR-TB cases with SLD ST* reported in EU/EEA, 2011 In 2011, the proportion of extensive drug resistant cases among cases with multidrug resistance in EU/EEA was 13.4% (range 0 – 40.0%). Figure 14: Country-specific proportion of extensively drug-resistant TB cases among TB cases with multi-drug resistance, EU/EEA, 2011 < 1% 1 to 4% 5 to 9% 10 to 19% ≥ 20% or Not included or Not included not reporting not reporting *SLD ST – second line drug susceptibility testing result 15
  • 16. Proportion of HIV positive TB cases among all TB cases with known HIV status in EU/ EEA, 2011 In 2011, the overall proportion of HIV positive TB cases among TB cases with known HIV status in EU/EEA was 4.7% (range 0 – 40%). Figure 15: Country-specific proportion of HIV positive TB cases among TB cases with known HIV status, EU/EEA, 2011 < 1% 1 to 1.9% 2 to 4.9% 5 to 9.9% ≥ 10% Not included or not reporting 16
  • 17. Treatment success rate for new pulmonary TB cases in EU/EEA*, 2010 The treatment success rate for new culture-confirmed pulmonary TB cases notified in 2010 was 76.8% (range: 0 – 91.4%). Figure 16: Treatment success rate for new culture-confirmed pulmonary TB cases notified in 2010 100 Treatment success (%) 80 60 40 20 0 * Five EU/EEA Member States did not report treatment outcome data. 17
  • 18. Treatment success rate for new pulmonary TB cases by year of reporting in EU/EEA, 2006−2010 The treatment success rate for new culture-confirmed pulmonary TB cases notified between 2006 and 2010 has slightly decreased from 79.5% in 2006 to 76.8% in 2010. Figure 17: Treatment success rate for new culture-confirmed pulmonary TB cases notified in 2006−2010 100 80 Treatment success (%) 79,5 79,2 79,5 78,9 76,8 60 40 20 0 2006 2007 2008 2009 2010 Year of reporting 18
  • 19. Treatment success rate for previously treated pulmonary TB cases in EU/EEA*, 2010 The treatment success rate for previously treated culture-confirmed pulmonary TB cases notified in 2010 was 53.7% (range 31.4 – 85.7%). Figure 18: Treatment success rate for previously treated culture-confirmed pulmonary TB cases notified in 2010 100 Treatment success (%) 80 60 40 20 0 * Iceland and Luxembourg reported zero previously treated TB cases in 2010. Seven EU/EEA Member States did not report stratified treatment outcome data 19
  • 20. Treatment success rate for all notified pulmonary TB cases in EU/EEA*, 2010 The treatment success rate for all confirmed pulmonary TB cases notified in 2010 was 74.3% (range 0 – 90.1%). Figure 19: Treatment success rate for all confirmed pulmonary TB cases notified in 2010 100 80 Treatment success (%) 60 40 20 0 * Five EU/EEA Member States did not report treatment outcome data 20
  • 21. Treatment success* rate for extra- pulmonary TB cases in EU/EEA**, 2010 The treatment success rate for extrapulmonary TB cases notified in 2010 was 82.2% (range 21.1 – 100%). Figure 20: Treatment success rate for extrapulmonary TB cases notified in 2010 100 80 Treatment success (%) 60 40 20 0 * Treatment success of extrapulmonary TB consists of cases reported as completed full course of anti-tuberculosis treatment ** Seven Member States did not report stratified treatment outcome data 21
  • 22. Treatment success rate for notified multidrug-resistant TB cases in EU/EEA*, 2009 The treatment success rate for all confirmed multidrug-resistant TB cases notified in 2009 was 31.6% (range 0 – 84.6%). Figure 21: Treatment success rate for all confirmed multidrug-resistant TB cases notified in 2009 100 80 Treatment success (%) 60 40 20 0 * Malta reported zero MDR TB cases in 2009, 11 Member States did not report treatment outcome data 22
  • 23. Treatment outcome for multidrug-resistant TB cases notified in 2007−2009 Treatment outcomes for multidrug-resistant TB cases did not improve between the 2007 and 2009 cohort, EU/EEA. Figure 22: Treatment outcome at 24 months for multidrug-resistant TB cases diagnosed in 2009, compared with cases diagnosed in 2007 and 2008 35 cohort 2009 (18 countries) 30 cohort 2008 (20 countries) 25 cohort 2007 (15 countries) Percentage 20 15 10 5 0 Success Died Failed Defaulted Still on Transferred or treatment unknown 23